Healthcare: Biotechnology: Takeaways from ENDO

Research evidence excerpt

Healthcare: Biotechnology: Takeaways from ENDO

Equity Research

16 June 2026 | 9:29PM EDT

We attended the Endocrine Society Annual Meeting (ENDO) and highlight Corinne Johnson

+1(917)343-1445 |

incremental learnings across multiple disease areas for our coverage group, corinne.johnson@gs.com

Goldman Sachs & Co. LLC

including: i) NBIX in both congenital adrenal hyperplasia (CAH), with 2-year data

Kevin Strang, Ph.D.

from Crenessity reinforcing long-term benefit (hormone control, cardiometabolic +1(212)357-7227 |

health, bone age, patient/caregiver satisfaction), and competitor CRNX (covered by kevin.strang@gs.comGoldman Sachs & Co. LLC

Richard Law) Ph2 data at 12 weeks that looked positive on androgen reduction with Erik Wong

glucocorticoid reduction (albeit small numbers/different timepoint used vs. +1(212)357-9964Goldman Sachs & Co.| erik.wong@gs.comLLC

Crenessity); ii) RYTM (in addition to Prader-Willi syndrome [PWS] data presented Anupam Srivastava

Saturday) presented data in hypothalamic obesity (HO) for 1-year oral bivamelagon +1(332)245-7980 | anupam.srivastava@gs.com

(biva) data that showed efficacy at least in line with injectable setmelanotide with Goldman Sachs India SPL

numerically better hyperpigmentation, which we view as incrementally positive in

the context of potential use in PWS; iii) AMLX‘s posters on Ph3 design for LUCIDITY

(data expected 3Q26) and on the economic burden of post-bariatric hypoglycemia

(PBH) in the U.S. (>$3.6B annually); and iv) TYRA poster on Ph2 design for

dabogratinib in achondroplasia (ACH), where the presenter noted interest/fast

enrollment with data expected in 4Q26 (following IR NMIBC data in August).

Details within.

Key takeaways

Within we highlight takeaways across a number of disease areas relevant to our